Our leadership team
Corporate officers
Bryan Hanson
Chief Executive Officer
Bryan Hanson is CEO of Solventum, an $8.2 billion independent healthcare company rooted in a history of diverse expertise spanning the industry – from medical surgical and dental solutions to health information management and purification and filtration. He leads 22,000 problem-solving professionals who work tirelessly every day to enable better, smarter, safer healthcare to improve lives and shape the future of health.
Previously known as 3M Health Care, Solventum has a long legacy of creating breakthrough solutions for our customers’ toughest challenges. By pioneering game-changing innovations at the intersection of health, material, and data science, Solventum is advancing solutions that change patient’s lives for the better – while empowering healthcare professionals to perform at their best. Solventum products and services span the healthcare ecosystem, which makes it uniquely positioned to transform patient experiences, improve outcomes and help reduce total cost of care while driving long-term value for shareholders.
Bryan is a visionary leader who is passionate about transformation and building award-winning organisations. Throughout his 33+ year-career he has successfully led, grown, and transformed global medical device businesses at Zimmer Biomet, Medtronic and Covidien to achieve greater innovation and commercial success and drive value for customers, patients and shareholders. He serves on the board of directors of Walgreens Boots Alliance, Inc.
Outside of work, Bryan enjoys spending time with his wife and five children, as well as a variety of fitness activities.
Board of directors
Carrie S. Cox
Former Chief Executive Officer, Humacyte, Inc.
Carrie S. Cox. Ms. Cox most recently served as the Chief Executive Officer of Humacyte, Inc., a then privately-held regenerative medicine company, between 2010 and 2018; in addition, she served as Chairman of the company’s board between 2013 and 2019, and she remained a member of its board until 2021, prior to its public offering. Ms. Cox served as Executive Vice President of Schering-Plough Corporation and President of Schering-Plough’s global pharmaceutical business between 2003 and 2009, when Schering-Plough merged with Merck. Prior to joining Schering-Plough, Ms. Cox served as President of Pharmacia Corporation’s global pharmaceutical business from 1997 until its merger with Pfizer Inc. in 2003. She currently serves as Chairman of Organon & Co. and Cartesian Therapeutics, Inc. and as a director of Texas Instruments Inc. She served on the Board of Directors of Cardinal Health Inc. from 2009 to 2023, on the Board of Directors of Celgene Corporation from 2009 until its acquisition by Bristol-Myers Squibb Company in 2019, as Chairman of the Board of Directors of electroCore, Inc. between 2018 and 2020, and as Chairman of the Board of Directors of Array BioPharma Inc. from 2018 until its acquisition by Pfizer Inc. in 2019. Ms. Cox is a graduate of the Massachusetts College of Pharmacy and has been named six times to FORTUNE Magazine’s list of the “50 Most Powerful Women in Business.”
Explore more
Contact us
Have a transformative idea you’d like to share? We’d love to hear about it.